Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyCigna Vafseo (vadadustat) Coverage Prior Auth | Op…
    Ask Trek AI about this page
    CurrentCignaPolicy IP0706

    Vafseo (vadadustat) for anemia in CKD on dialysis

    Customize your policy alerts

    Sign up for Cigna Policy IP0706 alerts

    Get alerted when Policy IP0706 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This coverage policy governs prior authorization and medical necessity criteria for Vafseo (vadadustat tablets) for treatment of anemia due to chronic kidney disease in adults receiving dialysis, and describes excluded uses. It applies to Cigna-administered health benefit plans as detailed in the policy.

    Policy Summary
    PayerCigna
    PolicyVafseo (vadadustat) for anemia in CKD on dialysis
    Policy CodePolicy IP0706
    Change TypeNo material change
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review DateAug 6, 2026
    Key ActionObtain prior authorization and document baseline hemoglobin and iron status; initial approvals are 6 months when criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18min age
    ≥3 monthsdialysis duration
    6 monthsinitial approval
    1 yearcontinuing approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <11 g/dL
    baseline Hgb

    Coverage Criteria for Vafseo (vadadustat)

    Anemia in a Patient with CKD who is on Dialysis

    Approve when ONE of the following (A or B) is met:

    A) Initial Therapy: Initial Therapy. Approve for 6 months if ALL of the following (i–vi) are met
    Initial Therapy criteria (i–vi): i. Patient is ≥ 18 years of age; ii. Patient has been receiving dialysis for at least 3 consecutive months; iii. Patient meets ONE of the following (a or b); iv. Patient has a baseline (prior to initiation of Vafseo) hemoglobin level < 11 g/dL; v. Patient is currently receiving iron therapy OR, according to the prescriber, patient has adequate iron stores; vi. Medication is prescribed by or in consultation with a nephrologist and preferred product criteria is met.

    See subcriteria for iii.

    iii subcriteria (a or b): a) Patient meets BOTH: (1) Patient is currently receiving an erythropoiesis-stimulating agent and transitioning to Vafseo; AND (2) Patient has a hemoglobin level ≤ 12.0 g/dL; OR b) Patient meets BOTH: (1) Patient is NOT currently receiving an erythropoiesis-stimulating agent; AND (2) baseline hemoglobin < 11 g/dL (see above).

    Examples of erythropoiesis-stimulating agents include epoetin alfa products (Epogen, Procrit, Retacrit), Aranesp, and Mircera.

    B) Continuing Therapy: Continuing Therapy. Approve for 1 year if ALL of the following (i–vi) are met

    For patients who have not received 6 months (24 weeks) of therapy or restarting, refer to Initial Therapy.

    Continuing Therapy criteria (i–vi): i. Patient is ≥ 18 years of age; ii. Patient has been receiving dialysis for at least 3 consecutive months; iii. Patient has a hemoglobin level ≤ 12.0 g/dL; iv. Patient is currently receiving iron therapy OR, according to the prescriber, patient has adequate iron stores; v. Medication is prescribed by or in consultation with a nephrologist; vi. According to the prescriber, patient has experienced a response to therapy (e.g., increase or stabilization in hemoglobin or reduction/absence of red blood cell transfusions).

    The following uses of Vafseo (vadadustat) are considered not medically necessary and will be denied: treatment of anemia in patients with chronic kidney disease who are not on dialysis; treatment of anemia associated with cancer; use in patients with active malignancy; treatment of anemia due to acute blood loss; concurrent use with erythropoiesis-stimulating agents (ESAs); concurrent use with Jesduvroq (daprodustat); and use to enhance athletic performance.

    No additional explicit exclusions are listed in the provided excerpt of this policy beyond those enumerated in the Conditions Not Covered section.

    Summary of Conditions Not Covered: Vafseo is not indicated and is considered not medically necessary for anemia in CKD patients who are not on dialysis; anemia associated with cancer; patients with active malignancy; anemia due to acute blood loss; concurrent use with erythropoiesis-stimulating agents or daprodustat (Jesduvroq); and for the purpose of enhancing athletic performance.

    Alternate excerpt: within the provided portion of the document there is no separate list labeled “not medically necessary” beyond the Conditions Not Covered section; therefore no additional exclusions are specified in this excerpt.

    Clinical Thresholds and Coding-Adjacent Values

    Hemoglobin thresholds
    Initiation hemoglobin thresholdBaseline hemoglobin < 11 g/dL (prior to initiation of Vafseo)
    Transition/continuing hemoglobin ceilingHemoglobin ≤ 12.0 g/dL for patients transitioning from an ESA or for continuing therapy
    Use when not receiving an ESAIf patient is not currently receiving an ESA, initiation requires baseline hemoglobin < 11 g/dL
    Approval durations tied to thresholdsInitial approval 6 months when initiation criteria met; continuing approval 1 year when hemoglobin ≤ 12.0 g/dL and response documented
    Documentation requirementBaseline hemoglobin value must be provided prior to initiation

    Prior Authorization, Step Therapy, and Documentation Requirements

    Prior Authorization

    Prior authorization required; specified approval durations

    Prior Authorization is required for benefit coverage of Vafseo. Approvals: initial therapy approved for 6 months when criteria are met; continuing therapy approved for 1 year when criteria are met.

    • Initial therapy: 6 months when Initial Therapy criteria (i–vi) are satisfied.
    • Continuing therapy: 1 year when Continuing Therapy criteria (i–vi) are satisfied.
    Step Therapy

    Employer plans may require trial and failure/intolerance of one ESA

    For certain employer plans, coverage may require that the patient has tried and, according to the prescriber, experienced inadequate efficacy or significant intolerance with one listed erythropoiesis-stimulating agent (epoetin alfa product, Aranesp, or Mircera).

    • Examples listed: epoetin alfa products (Procrit, Epogen, Retacrit), Aranesp (darbepoetin alfa), Mircera (methoxy polyethylene glycol-epoetin beta).

    Background on Vafseo (vadadustat)

    Background: Vafseo (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated for treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least 3 months. It is approved for use in adults on dialysis and carries safety concerns observed in non-dialysis CKD populations; accordingly, its use is restricted to the dialysis population per this policy.

    Key Definitions

    Vafseo (vadadustat) — definition and indication summary
    Drug and classVafseo (vadadustat) — vadadustat tablets, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
    IndicationTreatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least 3 months
    Limitations of useNot shown to improve quality of life, fatigue, or patient wellbeing; not a substitute for red blood cell transfusions
    Prescribing context in policyCovered with criteria for adults on dialysis when all initiation or continuing criteria are met (see hemoglobin and iron requirements)
    Erythropoiesis-stimulating agents (ESA) — examples
    DefinitionErythropoiesis-stimulating agents (ESA) — pharmacologic agents that stimulate red blood cell production
    Policy Summary
    PayerCigna
    PolicyVafseo (vadadustat) for anemia in CKD on dialysis
    Policy CodePolicy IP0706
    Change TypeNo material change
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review DateAug 6, 2026
    Key ActionObtain prior authorization and document baseline hemoglobin and iron status; initial approvals are 6 months when criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Vafseo (vadadustat)Clinical Thresholds and Coding-Adjacent ValuesPrior Authorization, Step Therapy, and Documentation RequirementsBackground on Vafseo (vadadustat)Key Definitions
  1. Employer-specific prior authorization rules may apply.
  2. Prior Authorization

    Prior authorization required; no additional PA process details in excerpt

    The provided document excerpt states that prior authorization is required but does not list additional separate prior authorization procedures or forms in this excerpt.

    • Policy statement: Prior Authorization is required and approvals are provided for the durations noted.
    • No additional PA process details are present in the excerpted sections.
    Step Therapy

    Employer-plan step requirement: trial of one ESA may be required

    Some employer plans may require trial and inadequate response or significant intolerance to ONE erythropoiesis-stimulating agent (epoetin alfa product, Aranesp, or Mircera) as reported by the prescriber.

    • Prescriber must document inadequate efficacy or significant intolerance to one listed ESA.
    • Examples of ESAs are provided in the policy text.
    Note

    No general step therapy requirements described in this excerpt

    This portion of the policy does not describe any universal step therapy requirements for Vafseo; step therapy is only noted for certain employer plans.

    • No broad step therapy program is specified in the main approval criteria.
    • Employer-specific rules are separately noted.
    Prior Authorization

    Prescriber specialty required for prior authorization (nephrologist preferred)

    Prior authorization requires that Vafseo be prescribed by or in consultation with a physician who specializes in the condition being treated; the policy specifies the medication should be prescribed by or in consultation with a nephrologist for the covered indications.

    • Because of specialized skills required and monitoring, prescriber must be a specialist or consult with one (nephrologist preferred).
    • Approval requires prescriber specialty as part of the PA criteria.
    Documentation Required

    Document baseline hemoglobin and iron status before initiation

    Provide baseline hemoglobin prior to initiation and documentation of iron status or current iron therapy, or a prescriber statement that the patient has adequate iron stores.

    • Baseline hemoglobin requirement for initiation: < 11 g/dL.
    • Document either current iron therapy or a prescriber statement of adequate iron stores.
    Documentation Required

    References/revision history; no additional documentation requirements here

    This section of the document contains references and revision history and does not add further specific provider documentation requirements beyond those already stated.

    • References and revision history are included on the final page.
    • No additional documentation steps are specified in these chunks.
    Denial Risk

    Do not use Vafseo for non-dialysis CKD anemia — coverage will be denied

    Use of Vafseo for anemia in chronic kidney disease patients who are NOT on dialysis is considered not medically necessary and will be denied.

    • Policy explicitly states Vafseo is not indicated and safety has not been established for CKD patients not on dialysis.
    • Coverage for non-dialysis CKD anemia is listed under 'Conditions Not Covered.'
    Denial Risk

    Excluded conditions that will lead to denial

    Do not prescribe Vafseo for anemia associated with cancer, active malignancy, anemia due to acute blood loss, or concomitant use with erythropoiesis-stimulating agents; these uses are listed as not medically necessary and will be denied.

    • Concurrent use with ESAs is not recommended and listed as a condition not covered.
    • Active malignancy and anemia due to acute blood loss are explicitly listed as excluded.
    Denial Risk

    No additional explicit denial triggers listed in this excerpt

    No explicit denial triggers (beyond the not medically necessary conditions and failure to meet coverage criteria) are stated in this part of the document.

    • Denials are tied to conditions listed under 'Conditions Not Covered' or failure to meet the specified coverage criteria.
    • No additional explicit denial triggers are provided in the excerpt.
    Examples — epoetin alfa productsEpoetin alfa products (e.g., Epogen, Procrit, Retacrit) — IV or SC formulations
    Example — darbepoetin alfaAranesp (darbepoetin alfa) — IV or SC injection
    Example — methoxy polyethylene glycol-epoetin betaMircera (methoxy polyethylene glycol-epoetin beta) — IV or SC injection